25.11.2016 • News

Barentz Takes Majority of Globe Ingredients

(c) Barentz
(c) Barentz

Dutch distributor Barentz has taken a majority stake in Globe Ingredients, an international trader and distributor of feed, food and pharmaceutical ingredients. The deal strengthens Barentz’ position as an animal nutrition provider and extends its business into new geographies. The size of the stake and financial terms were not disclosed. Globe Ingredients, known as Globe Fine Chemicals until 2016, is headquartered in Zwijndrecht, the Netherlands, with offices in Serbia, China and Colombia. Its core business is supplying vitamins and amino acids for the feed industry.

Hidde van der Wal, CEO of Barentz International, said the acquisition fits perfectly with its business plan toward 2025 in which it aims to acquire strategic companies that also expand its geographic reach. The two directors of Globe Ingredients  –  Martijn Krijgsman and Frank van Eeden – will continue to manage the company. “Globe Ingredients will benefit from the distribution network and expertise of Barentz while at the same time Barentz can spread its business worldwide in the sales and distribution of feed additives,” said van Eeden.

Barentz has made several acquisitions in the past two years, including US-based AmTech Ingredients, China’s New Skyport and Indonesia’s Astabumi in 2015. Its most recent venture was in February this year when it set up Barentz Middle East in partnership with Iranian trading firm Future Way Holding.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read